^
BIOMARKER:
PIK3CA mutation
i
Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
Entrez ID:
Related biomarkers:
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab + alpelisib + LJM-716
Sensitive
:
C3
Clin Cancer Res - 6d
PIK3CA mutation
HER2 Negative Breast Cancer
alpelisib
Sensitive
:
B
PIK3CA mutation
Breast Cancer
BKM120
Sensitive
:
B
PIK3CA mutation
Breast Cancer
alpelisib
Sensitive
:
B
PIK3CA mutation
Triple Negative Breast Cancer
GDC-0068
Sensitive
:
B
PIK3CA mutation
CRC
panitumumab
Resistant
:
B
PIK3CA mutation
HER2 Positive Breast Cancer
neratinib
Resistant
:
B
PIK3CA mutation
HER2 Positive Breast Cancer
lapatinib
Resistant
:
B
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab
Sensitive
:
B
PIK3CA mutation
CRC
atezolizumab + cobimetinib
Sensitive
:
B
PIK3CA mutation
HER2 Positive Breast Cancer
everolimus
Sensitive
:
B
PIK3CA mutation
NSCLC
erlotinib
Resistant
:
B
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab + MEN1611
Sensitive
:
C2
PIK3CA mutation
Uterine Cancer
copanlisib
Sensitive
:
C2
PIK3CA mutation
HER2 Positive Breast Cancer
MEN1611
Sensitive
:
C2
PIK3CA mutation
Breast Cancer
MEN1611
Sensitive
:
C2
PIK3CA mutation
Breast Cancer
GDC-0032
Sensitive
:
C2
PIK3CA mutation
SCCHN
alpelisib
Sensitive
:
C2
PIK3CA mutation
NSCLC
U3-1402
Sensitive
:
C3
PIK3CA mutation
Triple Negative Breast Cancer
everolimus
Sensitive
:
C3
PIK3CA mutation
Urothelial Cancer
pembrolizumab
Sensitive
:
C3
PIK3CA mutation
SCCHN
temsirolimus
Sensitive
:
C3
PIK3CA mutation
NSCLC
X-396
Resistant
:
C3
PIK3CA mutation
Breast Cancer
bevacizumab
Sensitive
:
C3
PIK3CA mutation
Breast Cancer
ribociclib
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our